ReviewFrontiers in medicine2026
Outcome observability in evidence on proton pump inhibitor-associated
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Evidence on proton pump inhibitor (PPI) exposure and Study design and setting: We conducted a structured methodological audit of evidence sources evaluating PPI exposure and CDI-related outcomes. Original observational reports and observational or randomized trial-based meta-analytic reports were retained as distinct evidence types. Methods: For each eligible reported result, we extracted the target outcome and risk set, PPI exposure contrast, time zero and exposure/outcome windows, outcome ascertainment, effect measure, event information, and data-source dependence. Four observability domains were coded as explicit/target-aligned (E), partial/proxy-based (P), unclear/misaligned (U), or aggregate/mixed (A). Codes were not summed, weighted, or dichotomized. Meta-analytic reports were described as aggregate evidence, and odds ratios, risk ratios, and hazard ratios were not treated as quantitatively interchangeable. Results: Eleven evidence sources contained an eligible PPI exposure contrast for a CDI-related outcome after one report was excluded during result-level reassessment. Eight addressed incident CDI, one addressed C. difficile detection without uniform confirmation of clinical CDI, one addressed severity among patients with established CDI, and one addressed mortality among patients with established CDI. Nine estimates were odds ratios, one was a risk ratio, and one was a hazard ratio. Temporal alignment and outcome ascertainment varied across original reports, while three meta-analytic reports combined heterogeneous component definitions. Two Swedish registry reports were treated as one overlapping data-source cluster. Conclusions: The included estimates did not represent one common PPI-CDI estimand. A result-specific outcome-observability profile can identify methodological non-comparability, but it is not a score of study quality, causal validity, statistical power, or likelihood of a positive result. The framework should be interpreted as a descriptive methodological audit rather than evidence that observability conditions explain the direction of reported associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.